New Psilocybin Study Finds Rapid Depression Relief After One Dose
There’s a new Swedish clinical trial that adds to the growing case for psilocybin as a fast acting depression treatment. The study, published in JAMA Network Open, found that one supervised dose of psilocybin, paired with psychotherapy, improved depression symptoms within days for some patients. The benefits lasted for months, though the effect appeared to fade over time.
New:Â Get Pre-Screened for a Psychedelic Clinical Trial
| Key Takeaway | Why It Matters |
|---|---|
| One psilocybin dose produced rapid improvement. | Patients showed measurable symptom relief as early as day 2. |
| The trial included psychotherapy support. | The treatment was not psilocybin alone. It included preparation and integration sessions. |
| Benefits lasted more than three months. | The effect was meaningful, but not permanent for every patient. |
| Some patients needed added support. | Severe anxiety occurred in two people after dosing. |
| Larger studies are still needed. | Researchers want more data on repeat dosing and maintenance care. |
What the Study Found
Researchers at Karolinska Institutet and the Brain Stimulation Clinic in Stockholm ran the trial with 35 adults who had moderate to severe recurrent depression.
Participants received either a single 25 milligram dose of psilocybin or niacin, an active placebo. Both groups also received five psychotherapy sessions across 17 days.
The psilocybin group improved more than the placebo group on the study’s main depression measure by day 8. Self reported symptoms began improving even earlier, around day 2.
By week 6, 53 percent of participants in the psilocybin group met remission criteria. In the placebo group, that number was 6 percent.
Those numbers explain why researchers described the findings as rapid and clinically meaningful. Depression treatment often takes weeks to show benefit. For people in serious distress, speed matters.
Why the Follow Up Matters
The study also followed patients for one year. That longer view is important.
Psilocybin’s advantage remained clear for several months, but the difference between groups was no longer significant at 12 months. That does not erase the early benefit. It does suggest that a single session may not be enough for long term relapse prevention.
The researchers pointed to repeat dosing or added maintenance care as possible next steps. That is where the field may be headed.
This is also where clinics and future treatment models will need more structure. A powerful acute response is valuable. Durable care requires planning, follow up, and clear support protocols.
A Promising Result With Real Caution
The trial did not report drug related serious adverse events. Most side effects were mild or moderate and passed.
Still, two people in the psilocybin group had persistent severe anxiety that required medical attention. That detail matters. It pushes back against the idea that psychedelic therapy is simply a breakthrough with no downside.
Screening matters. Preparation matters. So does support after the dosing session.
The Marijuana Moment report places this study within a larger wave of psychedelic research. Psilocybin is being studied for depression, addiction, and other mental health conditions. But this trial stands out because it used a randomized, double blind design and followed patients for a full year.
The takeaway is not that psilocybin is ready to replace standard depression care. It is that the evidence base keeps getting more serious.
For patients, clinicians, and policymakers, the next question is practical. How can promising results become safe, accessible treatment models that hold up beyond the first few months?
